Article info
Inflammatory bowel disease
Original research
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn’s disease stopping infliximab: when the remission state hides different types of residual disease activity
- Correspondence to Dr Nicolas Pierre, Laboratory of Translational Gastroenterology, GIGA-institute, University of Liege, Liege, Belgium; nicolas.pierre{at}uliege.be
Citation
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn’s disease stopping infliximab: when the remission state hides different types of residual disease activity
Publication history
- Received March 8, 2022
- Accepted August 17, 2022
- First published August 25, 2022.
Online issue publication
February 07, 2023
Article Versions
- Previous version (25 August 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.